In the latest look at the underlying components of the S&P 500 ordered by largest market capitalization, Zoetis Inc (Symbol: ZTS) has taken over the #296 spot from ResMed Inc. (Symbol: RMD), according to The Online Investor.  

	Market capitalization is an important data poi

Zoetis Takes Over #296 Spot From ResMed 

Key PointsZoetis's organic operational revenue fell 1% in the third quarter.

Zoetis: 3 Key Takeaways for Long-Term Investors

RPM International announced at its annual meeting of stockholders that its board of directors declared a regular quarterly cash dividend of $0.57 per share, payable on October 30, 2026, to stockholders of record as of October 20, 2026. This payment represents a 5.6% increase ove

Daily Dividend Report: RPM,CSX,ZTS,EPD,NWN

In the most recent trading session, Zoetis (ZTS) closed at $70.27, indicating a -1.87% shift from the previous trading day.

Zoetis (ZTS) Registers a Bigger Fall Than the Market: Important Facts to Note

PARSIPPANY, N.J., September 24, 2026--Zoetis Inc. (NYSE:ZTS) will host a webcast and conference call at 8:30 a.m. (ET) on Thursday, November 5, 2026. Chief Executive Officer Kristin Peck and Executive Vice President, Chief Financial Officer and Chief Operating Officer Jay Saccaro will review third quarter 2026 financial results and respond to questions from financial analysts.

Zoetis to Host Webcast and Conference Call on Third Quarter 2026 Financial Results

The companion animal diagnostics market is projected to grow from USD 3.56 billion in 2026 to USD 5.40 billion by 2031, registering an 8.7% CAGR. Growth is driven by rising pet healthcare spending, preventive care, chronic and infectious diseases, and advances in AI, molecular diagnostics, point-of-care testing and automated analyzers. Molecular diagnostics will record the fastest growth, while consumables remain the leading product segment. Asia Pacific is expected to be the fastest-growing reg

Companion Animal Diagnostic Market Forecasts Growth from $3.56B (2026) to $5.40B by 2031, Profiling IDEXX Laboratories & Zoetis

Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health solutions for the animal health industry in the United States and internationally. The company commercializes products primarily across companion animals comprising dogs, cats, and horses; and species, including livestock, such as cattle, swine, poultry, fish, and sheep. It also offers parasiticides, vaccines, dermatology, anti-infectives, pain and sedation, other pharmaceutical, and animal health diagnostics. In addition, the company provides animal health diagnostics, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, which include nutritionals, as well as products and services in biodevices, genetic tests, and precision animal health. It markets its products to veterinarians, livestock producers, and pet owners. The company has collaborated with Blacksmith Medicines, Inc. to discover and develop novel antibiotics for animal health. Zoetis Inc. was incorporated in 2012 and is headquartered in Parsippany, New Jersey.

Zoetis Inc. News